Urging the Congress of the United States to pass H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act or similar legislation dealing with stellate ganglion block therapy to veterans and members of the armed forces of the United States with post-traumatic stress disorder, during the 119th United States Congress.
House Resolution 157 is a nonbinding memorial urging Congress to pass, or reintroduce, federal legislation that would direct the U.S. Department of Veterans Affairs and the Department of Defense to provide stellate ganglion block (SGB) therapy for veterans and active-duty service members diagnosed with post-traumatic stress disorder (PTSD). The resolution frames SGB as an emerging, low-risk treatment that may relieve PTSD symptoms such as hyperarousal, exaggerated startle response, and anxiety, and it cites statistics on PTSD prevalence among veterans and the connection between untreated PTSD and suicide risk.
The resolution does not change Pennsylvania law or create a state program. Instead, it expresses the Pennsylvania House of Representatives’ support for federal action and directs copies of the resolution to the President, congressional leaders, and Pennsylvania’s congressional delegation. Its practical effect is advocacy: it seeks to influence federal veterans’ health policy and encourage broader access to SGB therapy for military populations.
The general sentiment reflected in the bill text and voting history is strongly supportive. The resolution passed the House Intergovernmental Affairs and Operations Committee unanimously on both an amendment and reporting the bill as amended, with 26 yeas and 0 nays in each recorded vote. The bill also notes support from the Pennsylvania National Guard Associations, the American Legion, and behavioral health clinicians, reinforcing a favorable posture toward the measure.
The main point of contention is not opposition to the resolution itself, but the underlying policy question of whether SGB therapy should be formally adopted and funded as a treatment for PTSD at the federal level. The resolution relies on claims that SGB is effective and low risk, but because it urges Congress to act rather than establishing a state standard, any debate is centered on the evidence base, medical appropriateness, and federal veterans’ health policy rather than Pennsylvania statutory law.
HR157 has no direct effect on Pennsylvania statutes, regulations, or state spending. It is a legislative expression of support that urges Congress to enact federal PTSD treatment legislation for veterans and service members, specifically to make stellate ganglion block therapy available through the VA and Department of Defense. Its impact is therefore political and advisory rather than legal, aimed at influencing federal veterans’ health policy and treatment access.
The sentiment around HR157 is overwhelmingly positive and supportive. The committee votes were unanimous, and the resolution cites backing from veterans’ organizations and behavioral health professionals. The bill’s framing emphasizes unmet treatment needs, suicide prevention, and expanded access to care for veterans and service members, which likely contributed to the lack of recorded opposition.
There is little direct contention in the available record, but the underlying issue is whether stellate ganglion block therapy should be recognized and provided as a standard PTSD treatment. Supporters argue it is low risk, has been used for decades, and may help veterans who do not benefit from current treatments. Any skepticism would likely focus on the strength of the clinical evidence, the appropriateness of federal adoption, and whether the therapy should be broadly covered by VA and DoD systems.